By Josh White
Date: Monday 13 Mar 2023
(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.
By Josh White
Date: Tuesday 17 Jan 2023
(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.
By Josh White
Date: Tuesday 18 Oct 2022
(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.
Currency | UK Pounds |
Share Price | 113.50p |
Change Today | 1.00p |
% Change | 0.89 % |
52 Week High | 185.00 |
52 Week Low | 49.98 |
Volume | 1,594,956 |
Shares Issued | 272.41m |
Market Cap | £309.19m |
RiskGrade | 461 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:31 | 16,689 @ 113.00p |
16:29 | 1,508 @ 114.20p |
16:28 | 3,179 @ 113.99p |
16:28 | 500 @ 112.50p |
16:27 | 2,500 @ 113.99p |
CEO | Alastair Smith |
CFO | Tony Peter Gardiner |
You are here: research